Among firms that offer health benefits with 200 or more workers, 16% of firms with 200 to 999 workers, 30% of firms with 1,000 to 4,999 workers, and 43% of firms with 5,000 or more workers cover GLP-1 agonists when used primarily for weight loss [Figure 13.16]
Appendix List of Abbreviations Sources and References VMR Research Methodology The 9-Phase Research Framework A comprehensive methodology integrating strategic market intelligence - from objective framing through continuous tracking
Lavie CJ, Arena R, Alpert MA, Milani RV, Ventura HO
Mounjaro (tirzepatide) is a GLP-1/GIP dual agonist, while Ozempic and Wegovy contain semaglutide, a GLP-1-only agent
You have more choice but less predictability
[1] Appropriate eye monitoring should be considered